CompletedPhase 1

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

United States10 participantsStarted 2010-08

Plain-language summary

Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients with actively growing pterygia, either surgical recurrences, or non-surgical primary lesions. Exclusion Criteria: * Pregnancy * History of CVA * Monocular patients * Minors

What they're measuring

Safety

Timeframe: Within the first 30 days after injection

Trial details

NCT IDNCT01169909

SponsorUniversity of New Mexico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-07

View on ClinicalTrials.gov More Pterygium trials